NRx Pharmaceuticals refiled its Abbreviated New Drug Application for KETAFREE™ and received FDA support, expecting a Q2 2026 GDUFA date. HOPE Therapeutics operates three revenue-generating facilities in Florida, with plans for six by year-end. NRx secured operating capital through July 2026 and anticipates revenue growth. NRx also received FDA Fast Track Designation for suicidal ideation treatment with NRX-100.

New Real-World Data supports D-cycloserine’s effectiveness in doubling the impact of Transcranial Magnetic Stimulation (TMS). NRx has expanded access to NRX-101 for use in depression, suicidality, and PTSD. NRx is pursuing two pathways for NRX-100, including an NDA for suicidal depression and an ANDA for preservative-free ketamine. NRx is working towards a Q2 2026 GDUFA date.

NRx has secured funding for drug development operations until July 2026 and expects to increase revenue. NRx received Fast Track Designation for NRX-100 for treating suicidal ideation. Real-World Data supports D-cycloserine’s effectiveness in augmenting the effects of TMS. NRx is also expanding access to NRX-101 in various mental health conditions.

HOPE Therapeutics now operates three revenue-generating facilities in Florida, with plans for more by year-end. NRx has secured operating capital until July 2026 and anticipates revenue growth. NRx also received Fast Track Designation for NRX-100. Real-World Data supports the effectiveness of D-cycloserine in enhancing TMS. HOPE Therapeutics provides a variety of treatments for mental health conditions.

Read more at GlobeNewswire: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third